A substantial portion of the budget for the Food and Drug Administration (FDA) is comprised of user fees, collected from the industries that the agency regulates. The FDA spends the money collected from the user fees for specific purposes, such as the expedited review and approval of drugs or medical devices. At present, the user fees are not exempt from the sequester, which went into effect in January of this year. Rep. Anna Eshoo, (D-Calif.), is a lead sponsor of a bipartisan House bill, the FDA Safety over Sequestration (SOS) Act, which would exempt the user fees from sequestration. She stated that “private dollars” should not be sacrificed in the name of policy. Proponents of the Act maintain that applying the sequester to the user fees would stifle medical innovation and patient access to “timely therapies.” The SOS Act has found support amongst prominent medical device groups as well.